EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Phosphodiesterase Type 5 Inhibitors in Male Reproduction: Molecular Mechanisms and Clinical Implications for Fertility Management

Aris Kaltsas iD, Fotios Dimitriadis iD, Athanasios Zachariou iD, Nikolaos Sofikitis, Michael Chrisofos iD

Cells · 15.01.2025 · 14 (2) · 120

DOI: 10.3390/cells14020120 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 15.01.2025. Verfasst von Aris Kaltsas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece. Hauptthemen laut MEDLINE: Reproduction, Fertility, Phosphodiesterase 5 Inhibitors, Cyclic Nucleotide Phosphodiesterases, Type 5. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphodiesterases, particularly the type 5 isoform (PDE5), have gained recognition as pivotal regulators of male reproductive physiology, exerting significant influence on testicular function, sperm maturation, and overall fertility potential. Over the past several decades, investigations have expanded beyond the original therapeutic intent of PDE5 inhibitors for erectile dysfunction, exploring their broader reproductive implications. This narrative review integrates current evidence from in vitro studies, animal models, and clinical research to clarify the roles of PDEs in effecting the male reproductive tract, with an emphasis on the mechanistic pathways underlying cyclic nucleotide signaling, the cellular specificity of PDE isoform expression, and the effects of PDE5 inhibitors on Leydig and Sertoli cell functions. Although certain findings suggest potential improvements in sperm motility, semen parameters, and a more favorable biochemical milieu for spermatogenesis, inconsistencies in study design, limited sample sizes, and inadequate long-term data temper definitive conclusions. Addressing these gaps through standardized protocols, larger and more diverse patient cohorts, and explorations of mechanistic biomarkers could pave the way for incorporating PDE5 inhibitors into evidence-based fertility treatment strategies. In the future, such targeted approaches may inform individualized regimens, optimize male reproductive outcomes, and refine the clinical application of PDE5 inhibitors as part of comprehensive male fertility management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ReproductionFertilityPhosphodiesterase 5 InhibitorsCyclic Nucleotide Phosphodiesterases, Type 5HumansAnimalsMaleSperm MotilityBiomarkersSpermatozoa

Stichwörter der Autor:innen

PDE5 inhibitorsandrologymale reproductionphosphodiesterase (PDE)reproductive endocrinologysperm motilityspermatogenesistesticular physiology

Substanzen

BiomarkersPhosphodiesterase 5 InhibitorsCyclic Nucleotide Phosphodiesterases, Type 5

Autor:innen und Institutionen

  • Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Department of Urology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Laboratory of Spermatology, Department of Urology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.

ORCID-Profile: Aris Kaltsas, Fotios Dimitriadis, Athanasios Zachariou, Michael Chrisofos

Zitieren

APA

Kaltsas, A., Dimitriadis, F., Zachariou, A., Sofikitis, N., & Chrisofos, M. (2025). Phosphodiesterase Type 5 Inhibitors in Male Reproduction: Molecular Mechanisms and Clinical Implications for Fertility Management. Cells, 14(2), 120. https://doi.org/10.3390/cells14020120

Vancouver

Kaltsas A, Dimitriadis F, Zachariou A, Sofikitis N, Chrisofos M. Phosphodiesterase Type 5 Inhibitors in Male Reproduction: Molecular Mechanisms and Clinical Implications for Fertility Management. Cells. 2025;14(2):120. doi:10.3390/cells14020120

BibTeX
@article{Kaltsas2025,
  author = {Kaltsas, Aris and Dimitriadis, Fotios and Zachariou, Athanasios and Sofikitis, Nikolaos and Chrisofos, Michael},
  title = {Phosphodiesterase Type 5 Inhibitors in Male Reproduction: Molecular Mechanisms and Clinical Implications for Fertility Management},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {120},
  doi = {10.3390/cells14020120}
}
Kostenlos starten →